8THF

SARS-CoV-2 BA.1 S-6P-no-RBD

Summary for 8THF

• Entry DOI: 10.2210/pdb8thf/pdb
• EMDB information: 41260
• Descriptor: Spike protein S1,Spike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• Functional Keywords: sars-cov-2, omicron spike, vaccine, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2; More
• Total number of polymer chains: 3
• Total formula weight: 353040.20

Authors

Bu, F.,Li, F.,Liu, B. (deposition date: 2023-07-15, release date: 2024-07-17, Last modification date: 2024-10-09)

Primary citation

Wang, G.,Verma, A.K.,Shi, J.,Guan, X.,Meyerholz, D.K.,Bu, F.,Wen, W.,Liu, B.,Li, F.,Perlman, S.,Du, L.
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV.
Npj Vaccines, 9:133-133, 2024

PubMed Abstract: Although Omicron RBD of SARS-CoV-2 accumulates many mutations, the backbone region (truncated RBD) of spike protein is highly conserved. Here, we designed several subunit vaccines by keeping the conserved spike backbone region of SARS-CoV-2 Omicron BA.1 subvariant (S-6P-no-RBD), or inserting the RBD of Delta variant (S-6P-Delta-RBD), Omicron (BA.5) variant (S-6P-BA5-RBD), or ancestral SARS-CoV-2 (S-6P-WT-RBD) to the above backbone construct, and evaluated their ability to induce immune responses and cross-protective efficacy against various SARS-CoV-2 variants and SARS-CoV. Among the four subunit vaccines, S-6P-Delta-RBD protein elicited broad and potent neutralizing antibodies against all SARS-CoV-2 variants tested, including Alpha, Beta, Gamma, and Delta variants, the BA.1, BA.2, BA.2.75, BA.4.6, and BA.5 Omicron subvariants, and the ancestral strain of SARS-CoV-2. This vaccine prevented infection and replication of SARS-CoV-2 Omicron, and completely protected immunized mice against lethal challenge with the SARS-CoV-2 Delta variant and SARS-CoV. Sera from S-6P-Delta-RBD-immunized mice protected naive mice against challenge with the Delta variant, with significantly reduced viral titers and without pathological effects. Protection correlated positively with the serum neutralizing antibody titer. Overall, the designed vaccine has potential for development as a universal COVID-19 vaccine and/or a pan-sarbecovirus subunit vaccine that will prevent current and future outbreaks caused by SARS-CoV-2 variants and SARS-related CoVs.

PubMed: 39054338
DOI: 10.1038/s41541-024-00922-z

Experimental method

ELECTRON MICROSCOPY (2.83 Å)